Cullinan Therapeutics, Inc.
CGEMCullinan Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class and best-in-class therapies for autoimmune diseases and oncology.
Earnings
Next report
Aug 6, 2026 (In 1 week)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By net margin
Profile
Cullinan Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class and best-in-class therapies for autoimmune diseases and oncology. The company leverages expertise in T cell engagers and small molecule inhibitors to create targeted treatments for high-impact diseases. Their pipeline is designed to address significant unmet medical needs through a combination of internal development and strategic licensing collaborations.
Cullinan positions itself as a developer of highly differentiated, off-the-shelf T cell engagers with superior potency and safety profiles compared to existing CAR T and monoclonal antibody therapies.
Questions, answered.
- What is Cullinan Therapeutics, Inc.'s market cap?
- Cullinan Therapeutics, Inc. (CGEM) has a market capitalization of $1.1B and trades on NASDAQ.
- Who are Cullinan Therapeutics, Inc.'s competitors?
- Cullinan Therapeutics, Inc.'s key competitors include Eli Lilly and Company, Amgen Inc., Johnson & Johnson, and others. These companies compete in similar markets and product categories.
- Who does Cullinan Therapeutics, Inc. partner with?
- Cullinan Therapeutics, Inc.'s notable partners include Taiho Pharmaceutical Co., Ltd., Chongqing Genrix Biopharmaceutical Co., Ltd., Adimab, LLC, and others.
- What subsidiaries does Cullinan Therapeutics, Inc. have?
- Cullinan Therapeutics, Inc.'s subsidiaries include Cullinan Florentine Corp., Cullinan Amber Corp..
- Where is Cullinan Therapeutics, Inc. headquartered?
- Cullinan Therapeutics, Inc. is headquartered in United States of America and employs approximately 85 people. It has been publicly traded since 2021.